Search results for " Suppressor"

showing 10 items of 462 documents

Image cytometric DNA analysis of mucosal biopsies in patients with primary achalasia.

2006

(P < 0.0001), and 9c- (P = 0.0001) exceeding rate with progredient DNA alterations in the respective order. CONCLUSION: The finding that DNA aneuploidy was identifi ed by image cytometry in esophageal specimens of patients with achalasia, which may be due to specifi c chromosomal alterations presenting as precancerous lesions in 27% of patients, leads us to conclude that image cytometry represents a valuable screening tool. Abstract AIM: To determine DNA aneuploidy in mucosal biopsies of achalasia patients for subsequent rapid diagnosis. METHODS: Biopsies from the middle third of the esophagus were obtained in 15 patients with achalasia. Immunohistochemical staining was carried out with mon…

AdultMalePathologymedicine.medical_specialtyEsophageal NeoplasmsBiopsyAchalasiaAneuploidyBiologydigestive systemBiopsyotorhinolaryngologic diseasesCarcinomamedicineHumansGenetic TestingFeulgen stainEsophagusAgedImage CytometryMucous Membranemedicine.diagnostic_testGastroenterologyDNAGeneral MedicineMiddle AgedAneuploidymedicine.diseaseImmunohistochemistrydigestive system diseasesEsophageal AchalasiaBasic ResearchKi-67 Antigenmedicine.anatomical_structureDysplasiaCarcinoma Squamous CellImage CytometryFemaleTumor Suppressor Protein p53Precancerous Conditions
researchProduct

CT-guided intratumoral gene therapy in non-small-cell lung cancer.

1999

The objective of this study was to prove the principle of CT-guided gene therapy by intratumoral injection of a tumor suppressor gene as an alternative treatment approach of incurable non-small-cell lung cancer. In a prospective clinical phase I trial six patients with non-small-cell lung cancer and a mutation of the tumor suppressor gene p53 were treated by CT-guided intratumoral gene therapy. Ten milliliters of a vector solution (replication-defective adenovirus with complete wild-type p53 cDNA) were injected under CT guidance. In four cases the vector solution was completely applied to the tumor center, whereas in two cases 2 ml aliquots were injected into different tumor areas. For the …

AdultMalePathologymedicine.medical_specialtyLung NeoplasmsTumor suppressor geneAdolescentGenetic enhancementGenetic VectorsDNA RecombinantInjections IntralesionalPolymerase Chain ReactionAdenoviridaeCarcinoma Non-Small-Cell LungBiopsyCarcinomaMedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyAdverse effectLung cancerAgedmedicine.diagnostic_testbusiness.industryGene Transfer TechniquesGeneral MedicineGenetic TherapyMiddle Agedmedicine.diseaseGenes p53Clinical trialTreatment OutcomeMutationFemalebusinessTomography X-Ray ComputedFollow-Up StudiesEuropean radiology
researchProduct

A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.

1998

Mutations of the tumor suppressor gene p53 are the most common genetic alterations observed in human cancer. Loss of wild-type p53 function impairs cell cycle arrest as well as repair mechanisms involved in response to DNA damage. Further, apoptotic pathways as induced by radio- or chemotherapy are also abrogated. Gene transfer of wild-type p53 was shown to reverse these deficiencies and to induce apoptosis in vitro and in preclinical in vivo tumor models. A phase I dose escalation study of a single intratumoral injection of a replication-defective adenoviral expression vector encoding wild-type p53 was carried out in patients with incurable non-small cell lung cancer. All patients enrolled…

AdultMalePathologymedicine.medical_specialtyLung NeoplasmsTumor suppressor geneAdolescentmedicine.medical_treatmentGenetic enhancementGenetic Vectorsmedicine.disease_causeAdenoviridaeInjectionsIn vivoCarcinoma Non-Small-Cell LungGeneticsMedicineHumansRNA MessengerMortalityLung cancerMolecular BiologyAgedRegulation of gene expressionChemotherapyExpression vectorbusiness.industryGene Transfer TechniquesGenetic TherapyMiddle Agedmedicine.diseaseGenes p53AdenoviridaeGene Expression Regulation NeoplasticTreatment OutcomeCancer researchMolecular MedicineFemalebusinessHuman gene therapy
researchProduct

P53 and bcl-2 immunoexpression in patients with oral lichen planus a nd oral squamous cell carcinoma

2012

Objective: The aim of this study was to determine by immunohistochemistry the presence and significance of p53 and bcl-2 proteins in oral lichen planus (OLP) and oral squamous cell carcinoma (OSCC). Study Design: We used 21 cases diagnosed as OLP 16 diagnosed as OSCC and four normal gingival biopsies taken from healthy patients were used as controls. Slides were processed for immunohistochemistry using anti-p53 and anti-bcl-2 monoclonal antibodies. Results: We found p53 immunoexpression in 71.4� OLP cases and 6� .7� OSCC cases, with no immunoexpres: We found p53 immunoexpression in 71.4� OLP cases and 6� .7� OSCC cases, with no immunoexpresWe found p53 immunoexpression in 71.4� OLP cases an…

AdultMalePathologymedicine.medical_specialtymedicine.drug_classMonoclonal antibodyMalignancyYoung Adultstomatognathic systemmedicineCarcinomaHumansIn patientBasal cellGeneral DentistryAgedMouth neoplasmOral Medicine and Pathologybusiness.industryMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]stomatognathic diseasesProto-Oncogene Proteins c-bcl-2OtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellImmunohistochemistryResearch-ArticleFemaleMouth NeoplasmsSurgeryOral lichen planusTumor Suppressor Protein p53businessLichen Planus Oral
researchProduct

Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma

2014

SASH1 (SAM and SH3 domain-containing protein 1) is a tumor suppressor gene involved in the tumorigenesis of a spectrum of solid cancers. Heterozygous SASH1 variants are known to cause autosomal-dominant dyschromatosis. Homozygosity mapping and whole-exome sequencing were performed in a consanguineous Moroccan family with two affected siblings presenting an unclassified phenotype associating an abnormal pigmentation pattern (hypo- and hyperpigmented macules of the trunk and face and areas of reticular hypo- and hyperpigmentation of the extremities), alopecia, palmoplantar keratoderma, ungueal dystrophy and recurrent spinocellular carcinoma. We identified a homozygous variant in SASH1 (c.1849…

AdultMaleSkin NeoplasmsDNA Mutational AnalysisMutation MissenseGenes RecessiveConsanguinityBiologyArticleConsanguinityKeratoderma PalmoplantarGeneticsmedicineHumansExomeGenetic Predisposition to DiseaseGenetics (clinical)Pigmentation disorderSkinFamily HealthGeneticsSiblingsTumor Suppressor ProteinsHomozygoteGenodermatosisSequence Analysis DNAFibroblastsmedicine.diseaseDisease gene identificationHyperpigmentationPedigreePalmoplantar keratodermaFemaleSkin cancermedicine.symptomSkin CarcinomaPigmentation DisordersEuropean Journal of Human Genetics
researchProduct

A novel constitutional mutation affecting splicing of retinoblastoma tumor suppressor gene intron 23 causes partial loss of pRB activity.

2005

Hereditary predisposition to retinoblastoma is caused by germ line mutations in the RB1 gene. Genetic counseling of affected individuals and accurate risk prediction for their families requires identification of the disease causing mutation. Furthermore, the nature of a mutation can determine genetic penetrance, disease presentation and prognosis. We describe, and functionally characterize here, a novel mutant allele of RB1 present in the germ line of a patient with sporadic bilateral retinoblastoma. The mutation generates an operational splice acceptor site resulting in a predicted protein product with loss of 81 amino acids from its carboxy terminus. We demonstrate that the aberrantly spl…

AdultMaleTumor suppressor geneRNA SplicingRetinal NeoplasmsDNA Mutational AnalysisRetinoblastoma ProteinGeneticsmedicineMissense mutationHumansDisease-causing MutationExpressivity (genetics)Genes RetinoblastomaGenetics (clinical)GeneticsbiologyRetinoblastomaRetinoblastoma proteinRetinoblastomamedicine.diseasePenetranceeye diseasesIntronsPedigreeMutation (genetic algorithm)Mutationbiology.proteinHuman mutation
researchProduct

Immunohistochemical analysis of vascular endothelial growth factor (VEGF) and p53 expression in pterygium from Tunisian patients.

2009

A pterygium is characterized by abnormal fibrovascular corneoconjunctival tissue. A number of investigations have attempted to elucidate this incompletely understood pathology. Since vascular endothelial growth factor (VEGF) and p53 are known to participate in tumor vascularization, our purpose was to study VEGF and p53 expression in active primary and recurrent pterygium from Tunisian patients. To this end, 15 cases of active primary pterygium and five cases of recurrent pterygium from Tunisia were studied by immunohistochemistry. Antibodies raised against VEGF and p53 were used to analyze the distribution and expression of these markers in pterygium and normal human conjunctiva were used …

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyConjunctivaTunisiaAngiogenesisPterygiumPathogenesisNeovascularizationImmunoenzyme Techniqueschemistry.chemical_compoundYoung AdultRecurrenceMedicineHumansCorneal NeovascularizationAgedbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseGenes p53eye diseasesPathophysiologyPterygiumVascular endothelial growth factormedicine.anatomical_structurechemistryImmunohistochemistryFemalesense organsmedicine.symptomTumor Suppressor Protein p53businessConjunctivaPathologie-biologie
researchProduct

Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular …

1999

Tumors associated with the VHL (von Hippel-Lindau) disease, such as hemangioblastomas and renal carcinomas and their sporadic counterparts, are cystic and well vascularized. Mutations of the VHL tumor-suppressor gene and elevated levels of vascular endothelial growth factor (VEGF) have been described in these tumors. The upregulation of VEGF has been shown in vitro as a consequence of alteration of the VHL gene. No comprehensive in vivo analysis has yet been carried out of the factors affecting tumor growth, vascularization, VEGF, and VHL expression. We performed immunohistochemistry and mRNA studies on primary sporadic renal carcinomas and matching normal renal tissue. We semiquantitativel…

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyendocrine system diseasesTumor suppressor geneAngiogenesisUbiquitin-Protein LigasesEndothelial Growth FactorsBiologyurologic and male genital diseasesmedicine.disease_causeLigaseschemistry.chemical_compoundDrug DiscoverymedicineHumansGenes Tumor SuppressorCarcinoma Renal CellGenetics (clinical)AgedLymphokinesKidneyNeovascularization PathologicVascular Endothelial Growth FactorsTumor Suppressor ProteinsProteinsMiddle Agedmedicine.diseaseKidney Neoplasmsfemale genital diseases and pregnancy complicationsGene Expression Regulation NeoplasticVascular endothelial growth factorVascular endothelial growth factor AClear cell renal cell carcinomamedicine.anatomical_structurechemistryVon Hippel-Lindau Tumor Suppressor ProteinMolecular MedicineFemaleCarcinogenesisClear cellJournal of Molecular Medicine
researchProduct

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct

Recovery after Heavy Resistance Exercise and Skeletal Muscle Androgen Receptor and Insulin-Like Growth Factor-I Isoform Expression in Strength Traine…

2011

The effects of heavy resistance exercise on skeletal muscle androgen receptor (AR) protein concentration and mRNAs of AR, insulin-like growth factor-I (IGF)-IEa, and mechano growth factor (MGF) expression were examined from biopsies of vastus lateralis (VL) muscle before and 48 hours after heavy resistance exercise (5 × 10 repetition maximum [RM] leg press and 4 × 10RM squats) in 8 adult strength trained men. The present exercise induced an acute decrease in maximal isometric force and increased serum total testosterone (T) and free testosterone (FT) concentrations. During 2 recovery days, maximal isometric force and subjective perception of physical fitness remained significantly lowered, …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhysical fitnessPhysical Therapy Sports Therapy and RehabilitationIsometric exerciseQuadriceps MuscleYoung AdultInsulin-like growth factorBasal (phylogenetics)Isometric ContractionInternal medicineSTAT5 Transcription FactormedicineHumansProtein IsoformsTestosteroneOrthopedics and Sports MedicineMuscle StrengthInsulin-Like Growth Factor ILeg pressCreatine KinaseTestosteroneUltrasonographybusiness.industryTumor Suppressor ProteinsSkeletal muscleResistance TrainingRecovery of FunctionGeneral MedicineAdaptation PhysiologicalAndrogen receptormedicine.anatomical_structureEndocrinologyPhysical FitnessReceptors AndrogenbusinessJournal of Strength and Conditioning Research
researchProduct